Biogen (BIIB) News Today $128.69 +0.23 (+0.18%) Closing price 04:00 PM EasternExtended Trading$127.84 -0.86 (-0.66%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Biogen Up Today?Toggle Visibility of Why Is Biogen Up Today?Biogen Inc. (NASDAQ:BIIB) shares have increased today amid a mix of analyst estimate revisions and insider activity. Key developments include: Positive Sentiment: William Blair raised its Q3 2025 EPS estimate for BIIB to $4.03 per share, surpassing consensus expectations. What is William Blair's Estimate for Biogen Q3 Earnings? Positive Sentiment: William Blair also boosted its Q2 2025 EPS forecast for BIIB to $4.11 from $4.09. William Blair Brokers Increase Earnings Estimates for Biogen Positive Sentiment: Wedbush lifted its Q2 2025 EPS estimate for BIIB to $4.15, up from $3.95. Wedbush Comments on Biogen's Q2 Earnings Neutral Sentiment: MarketBeat reports a consensus “Hold” rating on BIIB from 32 brokerages. Biogen Inc. Given Consensus Rating of "Hold" by Brokerages Neutral Sentiment: UBS reiterated its “Hold” rating on BIIB shares. UBS Remains a Hold on Biogen Negative Sentiment: Insider Rachid Izzar sold 2,223 BIIB shares at an average price of $135, trimming his stake by 25.99%. Rachid Izzar Sells 2,223 Shares of Biogen Inc. Stock Negative Sentiment: Wedbush cut its Q3 2025 EPS projection for BIIB to $3.81 from $3.85. Equities Analysts Issue Forecasts for Biogen Q3 Earnings Negative Sentiment: Leerink Partners lowered its FY 2025 EPS forecast for BIIB to $14.65 from $14.90. Posted 1h agoAI Generated. May Contain Errors. BIIB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Rachid Izzar Sells 2,223 Shares of Biogen Inc. (NASDAQ:BIIB) StockJuly 17 at 6:34 AM | insidertrades.comWhat is William Blair's Estimate for Biogen Q3 Earnings?July 17 at 6:31 AM | marketbeat.comWedbush Comments on Biogen's Q2 Earnings (NASDAQ:BIIB)July 17 at 6:09 AM | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Stake Lessened by Massachusetts Financial Services Co. MAJuly 17 at 5:48 AM | marketbeat.comCwm LLC Has $3.85 Million Holdings in Biogen Inc. (NASDAQ:BIIB)July 17 at 4:50 AM | marketbeat.comNew York State Common Retirement Fund Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB)July 17 at 4:19 AM | marketbeat.comCerity Partners LLC Has $5.52 Million Stake in Biogen Inc. (NASDAQ:BIIB)July 17 at 3:55 AM | marketbeat.com2,500 Shares in Biogen Inc. (NASDAQ:BIIB) Purchased by Alps Advisors Inc.July 17 at 3:54 AM | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Given Consensus Rating of "Hold" by BrokeragesJuly 17 at 2:29 AM | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Insider Sells $300,105.00 in StockJuly 16 at 6:47 PM | marketbeat.comEquities Analysts Issue Forecasts for Biogen Q3 EarningsJuly 16 at 6:46 AM | marketbeat.comWilliam Blair Brokers Increase Earnings Estimates for BiogenJuly 16 at 6:25 AM | marketbeat.comUBS Remains a Hold on Biogen (BIIB)July 16 at 3:09 AM | theglobeandmail.comLeerink Partnrs Has Weak Forecast for Biogen FY2025 EarningsJuly 15 at 2:49 AM | americanbankingnews.comBiogen Inc. (NASDAQ:BIIB) Holdings Raised by Leo Wealth LLCJuly 14 at 9:14 AM | marketbeat.comOVERSEA CHINESE BANKING Corp Ltd Buys 736,301 Shares of Biogen Inc. (NASDAQ:BIIB)July 14 at 8:20 AM | marketbeat.comBrown Advisory Inc. Sells 340,309 Shares of Biogen Inc. (NASDAQ:BIIB)July 14 at 4:16 AM | marketbeat.comEquities Analysts Issue Forecasts for Biogen FY2025 EarningsJuly 14 at 2:43 AM | marketbeat.comState of Michigan Retirement System Sells 23,800 Shares of Biogen Inc. (NASDAQ:BIIB)July 13, 2025 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Holdings Cut by Greenleaf TrustJuly 13, 2025 | marketbeat.comM&T Bank Corp Has $1.68 Million Stake in Biogen Inc. (NASDAQ:BIIB)July 13, 2025 | marketbeat.comBiogen Stock Short Interest Report | NASDAQ:BIIB - BenzingaJuly 11, 2025 | benzinga.comBiogen Stock Guidance | NASDAQ:BIIB - BenzingaJuly 11, 2025 | benzinga.comBiogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer?July 11, 2025 | msn.comBiogen’s Hold Rating: Navigating Current Challenges and Future OpportunitiesJuly 11, 2025 | tipranks.comWhat's Driving the Market Sentiment Around Biogen?July 10, 2025 | benzinga.comBiogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an ...July 10, 2025 | gurufocus.comBiogen (BIIB) Advances Phase 3 Study for Dravet Syndrome Treatment | BIIB Stock NewsJuly 10, 2025 | gurufocus.comBiogen (BIIB) Presents Promising Data from Zorevunersen Studies | BIIB Stock NewsJuly 10, 2025 | gurufocus.comNisa Investment Advisors LLC Decreases Stock Holdings in Biogen Inc. (NASDAQ:BIIB)July 10, 2025 | marketbeat.comStoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10, 2025 | businesswire.comBiogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJuly 10, 2025 | globenewswire.comBanque Pictet & Cie SA Acquires 4,780 Shares of Biogen Inc. (NASDAQ:BIIB)July 9, 2025 | marketbeat.comBank of New York Mellon Corp Lowers Stake in Biogen Inc. (NASDAQ:BIIB)July 9, 2025 | marketbeat.comBlackhawk Capital Partners LLC. Makes New $382,000 Investment in Biogen Inc. (NASDAQ:BIIB)July 8, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Acquires 4,019 Shares of Biogen Inc. (NASDAQ:BIIB)July 8, 2025 | marketbeat.comTeacher Retirement System of Texas Sells 12,285 Shares of Biogen Inc. (NASDAQ:BIIB)July 7, 2025 | marketbeat.comBiogen’s Felzartamab Study: A Potential Game-Changer for IgA NephropathyJuly 4, 2025 | tipranks.comKintegral Advisory LLC Lowers Position in Biogen Inc. (NASDAQ:BIIB)July 4, 2025 | marketbeat.comBiogen’s Litifilimab Study: A Long-Term Look at SLE TreatmentJuly 3, 2025 | tipranks.comBiogen’s Lecanemab Study: A Potential Game-Changer in Alzheimer’s Treatment?July 3, 2025 | tipranks.comNew York State Teachers Retirement System Has $14.73 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB)July 3, 2025 | marketbeat.comBiogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?July 1, 2025 | tipranks.comProvident Co of the Employees of the Hebrew University LTD Boosts Holdings in Biogen Inc. (NASDAQ:BIIB)July 1, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Acquires 25,464 Shares of Biogen Inc. (NASDAQ:BIIB)July 1, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Acquires 7,531 Shares of Biogen Inc. (NASDAQ:BIIB)July 1, 2025 | marketbeat.comBiogen Inc.: Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous NephropathyJune 30, 2025 | finanznachrichten.deRBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s marketJune 30, 2025 | finance.yahoo.comBiogen Initiates Global Phase 3 PROMINENT Study for Felzartamab in Adults with Primary Membranous Nephropathy (PMN)June 30, 2025 | quiverquant.comQBiogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous NephropathyJune 30, 2025 | financialpost.comF Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address BIIB Media Mentions By Week BIIB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIIB News Sentiment▼0.490.96▲Average Medical News Sentiment BIIB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIIB Articles This Week▼3723▲BIIB Articles Average Week Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amgen News Today Gilead Sciences News Today Ionis Pharmaceuticals News Today Moderna News Today Prothena News Today Sage Therapeutics News Today Cassava Sciences News Today Vertex Pharmaceuticals News Today Bristol Myers Squibb News Today Eli Lilly and Company News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIIB) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.